Copyright
©The Author(s) 2017.
World J Gastroenterol. Jan 21, 2017; 23(3): 540-546
Published online Jan 21, 2017. doi: 10.3748/wjg.v23.i3.540
Published online Jan 21, 2017. doi: 10.3748/wjg.v23.i3.540
Characteristic | n (%) |
Age (yr) | |
Median | 58 (37-74) |
Gender | |
Male | 63 (82.9) |
Female | 13 (17.1) |
Stage1 | |
II | 21 (27.6) |
III | 27 (35.5) |
IV | 28 (30.3) |
Fraction regimen | |
LCAF | 16 (21.1) |
CF | 60 (78.9) |
Number of chemotherapy cycles | |
1 | 8 (10.5) |
2 | 13 (17.1) |
3 | 7 (9.2) |
4 | 48 (63.2) |
Status | |
Survival | 17 (22.4) |
Dead | 53 (69.7) |
Lost to follow-up | 6 (7.9) |
- Citation: Zhu HT, Ai DS, Tang HR, Badakhshi H, Fan JH, Deng JY, Zhang JH, Chen Y, Zhang Z, Xia Y, Guo XM, Jiang GL, Zhao KL. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma. World J Gastroenterol 2017; 23(3): 540-546
- URL: https://www.wjgnet.com/1007-9327/full/v23/i3/540.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i3.540